← Back to list
Carboplatin shortage: Kyxata accepted for existing prior authorizations
Effective date
Jul 13, 2026
Identified
Jul 14, 2026
Summary
Cigna Healthcare will accept Kyxata as an alternative medication for patients with existing approved prior authorizations for Carboplatin due to a temporary manufacturing shortage. This eliminates the need for new prior authorization requests when substituting Kyxata for already-approved Carboplatin prescriptions covered under medical benefits. New Kyxata starts and other alternative medications still require standard prior authorization.
Get alerts when payers change rules like this one
We check Cigna and other payers every day and email you when a change matches your specialty and state.
Get Cigna alertsPolicy Monitoring is free. No card required.
What to do
Action · 5 steps
01Effective immediately (July 13, 2026): Billing and clinical staff must update internal workflows to recognize that patients with approved Carboplatin prior authorizations may fill prescriptions for Kyxata as a substitute without requiring a new prior authorization submission.
02Provider teams should communicate this exception to relevant oncology and treatment staff.
03Ensure that claims for Kyxata submitted against existing Carboplatin prior authorizations are processed without delay or denial.
04Note: This policy applies ONLY to medical benefit prescriptions—pharmacy benefit prescriptions continue to follow standard prior authorization processes.
05Monitor Cigna Healthcare communications for updates on when Carboplatin supply normalizes and this temporary policy expires.
Original notice
Carboplatin shortage: Kyxata accepted for existing prior authorizations
providernewsroom.com · Always check the source before changing claims.